Analysis10k / Blog
EN한국어ES
Company Snapshot · PFE

Pfizer (PFE): What This Company Actually Does

The short answer

Pfizer develops patent-protected drugs and vaccines for cardiovascular disease, cancer, and infectious disease, and makes its money charging premium prices while those patents hold — but about 40% of FY2025 revenue comes from products (Eliquis, Prevnar, Vyndaqel, Ibrance) whose patents expire between 2026 and 2029, the single biggest fact about this business.

Share price
$27.54
Market cap
~$157.0B
FY2025 revenue
$62.58B
Revenue facing 2026-29 patent expiry
~40%
Our take, in one linePfizer only looks reasonable if its pipeline can replace roughly 40% of revenue that loses patent protection by 2029. That single question is the investment case, and nothing in the filings settles it.

Pfizer sells patent-protected drugs through three wholesalers

Pfizer researches and develops patented drugs and vaccines, then sells them at premium prices for as long as patent exclusivity lasts. Most of the money doesn't come from patients directly — it moves through wholesalers to hospitals and pharmacies, and is ultimately paid by government programs like Medicare and private insurers.

R&D labs
~$10.4B/year, FY2025
→
Patented drugs & vaccines
Exclusive pricing while patent protection holds
→
3 wholesalers → hospitals/pharmacies
Paid mostly by Medicare and private insurers, not patients

The three largest wholesalers (McKesson, Cencora, Cardinal Health) collect more than half of revenue before it ever reaches a patient. Profit flows back into R&D ($10.4B in FY2025) and acquisitions (Metsera, Seagen). Source: 10-K FY2025, p.5, p.101.

Primary care leads, and the U.S. is 59% of sales

Revenue mix: Primary Care 42.9%, Specialty Care 28%, Oncology 26.9%, Other 2.2%Primary Care42.9%Specialty Care28%Oncology26.9%Other2.2%
Share of revenue, from the table below.
Revenue by therapeutic area — FY2025
AreaRevenueShare
Primary Care$26.8B42.9%
Specialty Care$17.5B28.0%
Oncology$16.8B26.9%
Other$1.4B2.2%

Pfizer reports Biopharma as its single segment, so segment-level operating margins aren't separately disclosed. Source: 10-K FY2025, p.101-102.

Geographically (FY2025): the U.S. is 59.3% ($37.1B), international markets are 40.7% ($25.5B) — with China the largest single international market at 5%, up slightly from 4% in 2024. International's share is actually down from a 2023 peak of 53%, when COVID vaccine sales were still concentrated overseas; it's been normalizing since.

Source: 10-K FY2025, p.6-7, p.36.

Three wholesalers control 54% of Pfizer's sales

Pfizer sells almost entirely through three pharmaceutical wholesalers, who together account for 54% of revenue: McKesson (25%), Cencora (16%), and Cardinal Health (13%).

More than half of revenue runs through three companiesThat concentration structurally limits Pfizer's negotiating leverage with its own distribution channel — losing or renegotiating terms with even one of the three would be a meaningful event.
  • Merck & Co. — its cancer drug Keytruda competes directly across much of Pfizer's oncology portfolio.
  • AbbVie — overlaps with Pfizer's Specialty Care business in immunology and oncology.
  • Bristol-Myers Squibb — a co-marketing partner on Eliquis, but a competitor in other cardiovascular and oncology products.

Source: 10-K FY2025, p.101 (wholesaler concentration).

40% of revenue faces a patent cliff by 2029

For a patent-driven pharma company, the number that matters most isn't quarterly revenue — it's how much of that revenue depends on patents that are about to expire. Once a patent lapses and generics enter, a drug's sales typically drop by more than half within a year or two.

Revenue facing patent expiration, 2026-2029 (FY2025)
ProductShare of FY2025 revenue
Eliquis12.7%
Prevnar10.4%
Vyndaqel10.2%
Ibrance6.6%
Combined~40%

R&D spending as a share of revenue was 16.7% in FY2025, up from 12.7% five years ago — the pace of reinvestment into the pipeline that has to eventually replace this ~40% of at-risk revenue.

Source: 10-K FY2025, p.7 (patent expiration table), p.101-102 (product revenue), p.51 (R&D spend); 10-K FY2022, p.51 (historical R&D/revenue).

A 30-year insider running the company since 2019

CEO Albert Bourla has led Pfizer since January 2019 and has also chaired the board since January 2020. A veterinarian and pharmacologist by training, he spent over 30 years at Pfizer before becoming CEO, including as COO starting in 2018 — a classic internal-promotion case. There's no founder involvement; Pfizer was founded in 1849 by Charles Pfizer, and that family has been out of management for generations. All directors and executives combined hold under 1% of shares; the largest holders are index funds — Vanguard (8.97%), BlackRock (7.70%), and State Street (5.10%) — none of which are activist investors.

Source: DEF 14A 2026, beneficial ownership and executive officer tables.

Three years without a single buyback

Pfizer raised its dividend modestly for three straight years — $1.65/share (2023) to $1.69 (2024) to $1.72 (2025). Buybacks, on the other hand, have been zero for three consecutive years (2023-2025). A $10B repurchase authorization from 2018 still has $3.3B unused, but management has paused buybacks entirely to preserve financial flexibility after funding the $43B Seagen acquisition with debt.

Debt from Seagen is still shaping capital allocationThree straight years without a single dollar of buybacks is unusual for a company this size — a direct, ongoing consequence of financing the 2023 Seagen acquisition with debt rather than cash or stock.

Source: 10-K FY2025, p.75.

What breaks Pfizer: the cliff arrives before the pipeline

Failure scenario If patents on major products like Eliquis, Prevnar, and Vyndaqel expire as scheduled between 2026 and 2029 and the pipeline doesn't produce a large enough replacement in time, Pfizer becomes a company that loses roughly 40% of its revenue within just a few years.
  • Patent cliff — Eliquis could face generic competition as early as November 2026 (on the compound patent) or as late as 2028 (under settlement terms). Prevnar, Vyndaqel, Ibrance, and Xtandi all have patents expiring in the same 2026-2029 window, threatening roughly 40% of revenue at once.
  • Wholesaler concentration — McKesson, Cencora, and Cardinal Health together account for 54% of revenue, structurally limiting Pfizer's price-negotiation leverage with its own distribution channel.
  • Government price controls (the IRA) — under the U.S. Inflation Reduction Act, the government now has authority to directly negotiate Medicare drug prices, and larger-revenue products are more likely to be selected for negotiation.

Source: 10-K FY2025, p.7 (patent expiration table), p.16-26 (Item 1A Risk Factors), p.101 (wholesaler concentration).

COVID boom, COVID bust, and the Seagen debt

Revenue: 2021 81,288, 2022 100,330, 2023 59,553, 2024 63,627, 2025 62,579. Free cash flow: 2021 29,869, 2022 26,031, 2023 4,793, 2024 9,835, 2025 9,07581,28829,8692021100,33026,031202259,5534,793202363,6279,835202462,5799,0752025
RevenueFree cash flowSame figures as the table below.
Operating margin by year: 2021 23.9%, 2022 34.8%, 2023 2.1%, 2024 19.5%, 2025 22.8%23.9%34.8%2.1%19.5%22.8%20212022202320242025
Operating margin, taken from the parentheses in the operating-income row below.
$ millions
20212022202320242025
Revenue81,288100,33059,55363,62762,579
YoY growth—+23.4%-40.6%+6.8%-1.6%
Operating income (margin)19,433 (23.9%)34,944 (34.8%)1,279 (2.1%)12,411 (19.5%)14,244 (22.8%)
Free cash flow29,86926,0314,7939,8359,075
Total debt38,43635,82971,88864,35164,795
2023 was reshaped by two things at onceTotal debt roughly doubled ($36B→$72B) to fund the debt-financed $43B Seagen acquisition, while operating margin collapsed from 34.8% to 2.1% as COVID vaccine and treatment sales crashed and one-time acquisition costs hit the same year.

Operating income = revenue minus cost of sales, SG&A, R&D, acquired-IPR&D, amortization of intangibles, and restructuring (derived by exclusion of other income/expense). FCF = operating cash flow minus capex. Total debt = short-term borrowings (including current portion of long-term debt) plus long-term debt. Source: 10-K FY2025, p.51, p.55, p.59-60; 10-K FY2022, p.46; 10-K FY2024, p.56.

Open questions: Metsera, the COVID floor, Eliquis litigation

  • When Metsera, the obesity-drug company acquired in November 2025, will start contributing meaningful revenue isn't disclosed here — the Q1 FY2026 earnings call would need to be checked.
  • Where Comirnaty and Paxlovid (COVID vaccine and treatment) revenue, in decline since 2023, will eventually bottom out isn't yet clear from these filings.
  • The final outcome of Eliquis patent litigation — including whether generics could enter as early as November 2026 — remains an open legal question not resolved in this data.
Built from Pfizer's 10-K filings for FY2021 through FY2025 and DEF 14A 2026, plus a web search for the current share price (Investing.com, Sept 2, 2026). This is a research summary, not investment advice — verify against the original filings before acting.

What we'd watch next

These three checks would show whether this read is holding up. They are prompts for your own follow-up, not predictions.

  • Revenue facing expiryAbout 40% comes from Eliquis, Prevnar, Vyndaqel and Ibrance.
  • Metsera contributionWhen the obesity acquisition adds revenue is unknown. Check Q1 FY2026.
  • Eliquis litigationGenerics could arrive as early as November 2026. Follow the case.

Frequently asked questions

How does Pfizer make money?

Pfizer develops patented drugs and vaccines for cardiovascular disease, cancer, and infectious disease, then sells them at premium prices for as long as patent protection lasts. Roughly 54% of revenue flows through just three wholesalers (McKesson, Cencora, Cardinal Health), and the ultimate payers are mostly governments (Medicare) and private insurers, not patients directly.

What is Pfizer's biggest risk right now?

A patent cliff. About 40% of FY2025 revenue comes from four products — Eliquis, Prevnar, Vyndaqel, and Ibrance — whose patents expire between 2026 and 2029. Once a patent expires and generics enter, a drug's revenue typically falls by more than half within one to two years.

What is Pfizer's market cap?

As of this article's data, Pfizer's market cap was about $162.3B, on FY2025 revenue of $62.58B.